Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation

Journal of Clinical Oncology

Volumn 31, Issue 1, 2013, Pages 39-48

  Icheva, Vanya ^a   Kayser, Simone ^a   Wolff, Daniel ^c   Tuve, Sebastian ^d   Kyzirakos, Christina ^b   Bethge, Wolfgang ^a   Greil, Johann ^e   Albert, Michael H ^f   Schwinger, Wolfgang ⁱ   Nathrath, Michaela ^g,h   Schumm, Michael ^a   Stevanovic, Stefan ^b   Handgretinger, Rupert ^a   Lang, Peter ^a   Feuchtinger, Tobias ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g INSTITUTE OF EPIDEMIOLOGY   (Germany)

^h Children's Hospital   (Germany)

ⁱ ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BUSULFAN; CIDOFOVIR; CLOFARABINE; CYCLOSPORIN; DEXAMETHASONE; EPSTEIN BARR VIRUS ANTIGEN 1; ETOPOSIDE; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 2; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VALACICLOVIR;

ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL ISOLATION; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CYTOKINE RELEASE; EPSTEIN BARR VIRUS INFECTION; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; IN VIVO STUDY; MORTALITY; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; SCHOOL CHILD; TREATMENT RESPONSE; VIREMIA; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ADOLESCENT; ADOPTIVE TRANSFER; ADULT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HERPESVIRUS 4, HUMAN; HUMANS; INTERFERON-GAMMA; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; YOUNG ADULT;

EID: 84871760755     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.8495     Document Type: Article

References (39)

1. Ocheni S, Kroeger N, Zabelina T, et al: EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 42:181-186, 2008
2. Handgretinger R, Lang P, Schumm M, et al: Immunological aspects of haploidentical stem cell transplantation in children. Ann N Y Acad Sci 938:340-357, 2001; discussion 357-358
3. Mohty M, Jacot W, Faucher C, et al: Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 17:2168-2177, 2003
4. Chiusolo P, Metafuni E, Cattani P, et al: Prospective evaluation of Epstein-Barr virus reactivation after stem cell transplantation: Association with monoclonal gammopathy. J Clin Immunol 30:894-902, 2010
5. Tran H, Nourse J, Hall S, et al: Immunodeficiency-associated lymphomas. Blood Rev 22:261-281, 2008
6. Meij P, van Esser JW, Niesters HG, et al: Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 101:4290-4297, 2003
7. van Esser JW, van der Holt B, Meijer E, et al: Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 98:972-978, 2001
8. Buyck HC, Ball S, Junagade P, et al: Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia. Bone Marrow Transplant 43:813-816, 2009
9. Lewin SR, Heller G, Zhang L, et al: Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood 100:2235-2242, 2002
10. Bahceci E, Epperson D, Douek DC, et al: Early reconstitution of the T-cell repertoire after non-myeloablative peripheral blood stem cell transplantation is from post-thymic T-cell expansion and is unaffected by graft-versus-host disease or mixed chimaerism. Br J Haematol 122:934-943, 2003
11. Wagner HJ, Cheng YC, Huls MH, et al: Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 103:3979-3981, 2004
12. Heslop HE: How I treat EBV lymphoproliferation. Blood 114:4002-4008, 2009
13. Heslop HE, Li C, Krance RA, et al: Epstein-Barr infection after bone marrow transplantation. Blood 83:1706-1708, 1994
14. Comoli P, Basso S, Zecca M, et al: Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 7:1648-1655, 2007
15. O'Reilly RJ, Doubrovina E, Trivedi D, et al: Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants. Immunol Res 38:237-250, 2007
16. Slobod KS, Benaim E, Woodruff L, et al: T cell immunotherapeutic populations control viral infections in bone marrow transplant recipients. Immunol Res 24:289-301, 2001
17. Gustafsson A, Levitsky V, Zou JZ, et al: Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95:807-814, 2000
18. Moosmann A, Bigalke I, Tischer J, et al: Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 115:2960-2970, 2010
19. Dong L, Gao ZY, Chang LJ, et al: Adoptive transfer of cytomegalovirus/Epstein-Barr virus-specific immune effector cells for therapeutic and preventive/preemptive treatment of pediatric allogeneic cell transplant recipients. J Pediatr Hematol Oncol 32:e31-e37, 2010
20. Uhlin M, Okas M, Gertow J, et al: A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother 59:473-477, 2010
21. Heslop HE, Slobod KS, Pule MA, et al: Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925-935, 2010
22. Rooney CM, Smith CA, Ng CY, et al: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549-1555, 1998
23. Riddell SR, Watanabe KS, Goodrich JM, et al: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238-241, 1992
24. Leen AM, Myers GD, Sili U, et al: Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12:1160-1166, 2006
25. Merlo A, Turrini R, Dolcetti R, et al: Adoptive cell therapy against EBV-related malignancies: A survey of clinical results. Expert Opin Biol Ther 8:1265-1294, 2008
26. Gattinoni L, Klebanoff CA, Palmer DC, et al: Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115:1616-1626, 2005
27. Feuchtinger T, Lang P, Hamprecht K, et al: Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy. Exp Hematol 32:282-289, 2004
28. Feuchtinger T, Matthes-Martin S, Richard C, et al: Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 134:64-76, 2006
29. Feuchtinger T, Richard C, Joachim S, et al: Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother 31:199-206, 2008
30. Feuchtinger T, Opherk K, Bethge WA, et al: Adoptive transfer of pp65 specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116:4360-4367, 2010
31. Jones K, Nourse JP, Morrison L, et al: Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders. Blood 116:2245-2252, 2010
32. Young LS, Rickinson AB: Epstein-Barr virus: 40 years on. Nat Rev Cancer 4:757-768, 2004
33. Demachi-Okamura A, Ito Y, Akatsuka Y, et al: Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells. Cancer Sci 99:1633-1642, 2008
34. Meyer VS, Drews O, Günder M, et al: Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands. J Proteome Res 8:3666-3674, 2009
35. Stemberger C, Huster KM, Koffler M, et al: A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets. Immunity 27:985-997, 2007
36. Fujita Y, Leen AM, Sun J, et al: Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother 31:665-674, 2008
37. Sun JC, Williams MA, Bevan MJ: CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 5:927-933, 2004
38. Bevan MJ: Helping the CD8(+) T-cell response. Nat Rev Immunol 4:595-602, 2004
39. Melenhorst JJ, Leen AM, Bollard CM, et al: Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 116:4700-4702. 2010